Although the 2021 WHO-CNS21 classification no longer categorizes IDH-mutant gliomas as GBM, we have chosen to retain IDH1-mutant gliomas in our analysis to ensure consistency across datasets and alignment with historical GBM molecular classifications. This evidence concerns the gene IDH1 and central nervous system cancer.